Peningkatan Deteksi Dini Kanker Serviks melalui Skrining HPV DNA kepada Masyarakat di Institut Teknologi Sepuluh Nopember
Isi Artikel Utama
Abstrak
Kanker serviks merupakan penyebab kematian paling sering kedua akibat kanker pada wanita di Indonesia, dengan sebagian besar kasus berhubungan dengan infeksi persisten Human Papillomavirus (HPV) risiko tinggi. Deteksi dini melalui skrining berbasis HPV Deoxyribonucleic Acid (DNA) direkomendasikan sebagai metode paling sensitif untuk mencegah progresi lesi prakanker menjadi kanker invasif.Kegiatan pengabdian masyarakat ini bertujuan meningkatkan cakupan deteksi dini kanker serviks di lingkungan Institut Teknologi Sepuluh Nopember (ITS) melalui program skrining HPV DNA. Kegiatan melibatkan peserta perempuan diatas 30 tahun dan mencakup edukasi kesehatan reproduksi wanita, pemeriksaan HPV DNA secara gratis, serta survei kepuasan layanan. Hasil skrining HPV DNA menunjukkan bahwa 75 peserta (97%) memiliki hasil negatif untuk HPV risiko tinggi (High Risk-HPV atau HR-HPV) dan 2 peserta (3%) memiliki hasil positif untuk HR-HPV. Selain itu, survei kepuasan menunjukkan sebagian besar peserta menilai proses layanan sangat baik, terutama pada keramahan petugas (96% tingkat tertinggi), manfaat pemeriksaan (88%), serta kejelasan prosedur dan hasil pemeriksaan. Peserta juga memberikan masukan agar kegiatan serupa dilakukan secara rutin dan diperluas untuk skrining penyakit lain yang dapat dicegah. Program ini menunjukkan bahwa skrining HPV DNA dapat diterima dengan baik, meningkatkan literasi kesehatan, dan berpotensi menjadi model implementasi deteksi dini berkelanjutan di institusi pendidikan.
Rincian Artikel
Artikel ini berlisensi Creative Commons Attribution-NonCommercial 4.0 International License.
Referensi
1. World Health Organization, WHO recommends DNA testing as a first-choice screening method for cervical cancer prevention; 2021.
2. Choi S, Ismail A, Pappas-Gogos G, Boussios S. HPV and Cervical Cancer: A Review of Epidemiology and Screening Uptake in the UK. Pathogens 2023;12(2):298.
3. Pareek S, Jain U, Tikadar M, Kumar P, Pudake RN, Chauhan N. Advancements and future predictions on diagnostic approaches towards cervical cancer through nanotechnology-based sensors for detection of HPV. Clinical Oncology Research 2021;4(6):1–7.
4. Kivistik A, Lang K, Baili P, Anttila A, Veerus P. Women’s knowledge about cervical cancer risk factors, screening, and reasons for non-participation in cervical cancer screening programme in Estonia. BMC Women’s Health 2011;11:43.
5. Gichangi P, Estambale B, Bwayo J, Rogo K, Ojwang S, Opiyo A, et al. Knowledge and practice about cervical cancer and Pap smear testing among patients at Kenyatta National Hospital, Nairobi, Kenya. International Journal of Gynecological Cancer 2003;13(6):827–833.
6. GLOBOCAN, Estimated age-standardized incidence rates (World) in 2018, worldwide, females, all ages; 2018.
7. Komisi Penanggulangan Kanker Nasional. Pedoman Nasional Pelayanan Kedokteran Kanker Serviks. Jakarta: Kementerian Kesehatan RI; 2017.
8. Cecilia NC, Rosliza AM, Suriani I. Global burden of cervical cancer: a literature review. International Journal of Public Health and Clinical Sciences 2017;4(2):10–18.
9. Komisi Penanggulangan Kanker Nasional. Panduan Penatalaksanaan Kanker Serviks. Jakarta: Kementerian Kesehatan RI; 2017.
10. Denny L. Cervical cancer: prevention and treatment. Discovery Medicine 2012;14(75):125–131.
11. Murillo R, Herrero R, Sierra MS, Forman D. Etiology of cervical cancer (C53) in Central and South America. Lyon: International Agency for Research on Cancer; 2016.
12. Boardman CH, Cervical cancer; 2019.
13. Johnson CA, James D, Marzan A, Armaos M. Cervical cancer: an overview of pathophysiology and management. Seminars in Oncology Nursing 2019;35(2):166–174.
14. Farghaly SA, editor. Uterine Cervical Cancer: Clinical and Therapeutic Perspectives. Switzerland: Springer; 2019.
15. Huang S, Tang N, Mak WB, Erickson B, Salituro J, Li Y, et al. Principles and analytical performance of Abbott RealTime High Risk HPV test. Journal of Clinical Virology 2009;45:S13–S17.
16. Zaravinos A, Mammas IN, Sourvinos G, Spandidos DA. Molecular detection methods of human papillomavirus (HPV). The International Journal of Biological Markers 2009;24(4):215–222.
17. Eide ML, Debaque H. HPV detection methods and genotyping techniques in screening for cervical cancer. Annales de Pathologie 2012;32(6):e15–e23.
18. Vet JN, De Boer MA, Van den Akker BE, Siregar B, Budiningsih S, Tyasmorowati D, et al. Prevalence of human papillomavirus in Indonesia: a population-based study in three regions. British Journal of Cancer 2008;99(1):214–218.
19. Utami TW, Nuranna L, Rahman SA, Irzami R, Utama A, Purwoto G, et al. A decade data of HPV genotypes in metropolitan regions of Indonesia: paving the way for a national cervical cancer elimination strategy. Journal of Gynecologic Oncology 2025;36(6):e85.
20. Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJ, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. The Lancet 2014;383(9916):524–532.
21. Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. The Lancet Global Health 2020;8(2):e191–e203.
22. Perkins RB, Guido RS, Castle PE, Chelmow D, Einstein MH, Garcia F, et al. 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. Journal of Lower Genital Tract Disease 2020;24(2):102–131.